Nel ASA

Regulatory Filings • Jan 23, 2014

DiaGenic reports AMYtectT study results

DiaGenic reports AMYtectT study results

DiaGenic reports final results from an exploratory study that examines

the agreement between gene expression in blood and brain amyloid PET

imaging. In a patient population of 144 patients, a gene expression

biomarker was identified that demonstrated an agreement of 69% with

brain amyloid PET imaging.

The primary goal of this exploratory study was to identify a gene

expression biomarker which detects whether an individual has normal or

elevated levels of amyloid in the brain as determined by brain amyloid

PET imaging. The subsequent goal was to develop an IVD multivariate

index assay test, AMYtectT. The study included 144 patients from

clinical centers coordinated by Lund University in Sweden, of which 118

were diagnosed with suspected mild cognitive impairment and 26 were

healthy controls. Blood samples were collected and brain amyloid PET

scans using GE Healthcare's investigational [18F] Flutemetamol tracer

were performed for all patients. The results show an agreement of 69%

between gene expression in blood and brain amyloid using PET imaging as

the reference.

"This study showed a significant correlation between a gene expression

biomarker candidate and brain amyloid PET imaging. This is a novel and

encouraging result in the quest to identify a blood test to screen for

early Alzheimer's patients. However, the correlation reached with the

current biomarker panel is not sufficient to warrant clinical

development of AMYtect", said Paul de Potocki, CEO at DiaGenic.

For more information, contact:

Paul de Potocki, CEO at DiaGenic, telephone: +47 2324 8950

About DiaGenic ASA

DiaGenic is an innovative diagnostic company that seeks to create value

for patients, partners and investors by developing patient friendly in

vitro diagnostic (IVD) products for early detection of diseases. The

company's proprietary concept implies that a disease evokes systemic

responses in the blood unique for the disease, and which can be measured

by using blood samples. DiaGenic is a world leader in identifying gene

expression signatures in blood and is focused on the development of IVD

biomarker products in the field of Alzheimer's disease. The company

protects its technology through an extensive patent portfolio. DiaGenic

is listed on the Oslo Stock Exchange.